These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 29696406)

  • 1. Cancer-adipose tissue interaction and fluid flow synergistically modulate cell kinetics, HER2 expression, and trastuzumab efficacy in gastric cancer.
    Akutagawa T; Aoki S; Yamamoto-Rikitake M; Iwakiri R; Fujimoto K; Toda S
    Gastric Cancer; 2018 Nov; 21(6):946-955. PubMed ID: 29696406
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trastuzumab Inhibits Growth of HER2-Negative Gastric Cancer Cells Through Gastrin-Initialized CCKBR Signaling.
    Cui Y; Li SB; Peng XC; Wu J; Fu GH
    Dig Dis Sci; 2015 Dec; 60(12):3631-41. PubMed ID: 26173505
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interaction between adipose tissue stromal cells and gastric cancer cells in vitro.
    Nomoto-Kojima N; Aoki S; Uchihashi K; Matsunobu A; Koike E; Ootani A; Yonemitsu N; Fujimoto K; Toda S
    Cell Tissue Res; 2011 May; 344(2):287-98. PubMed ID: 21384185
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual PI3K/mTOR inhibitor BEZ235 exerts extensive antitumor activity in HER2-positive gastric cancer.
    Zhu Y; Tian T; Zou J; Wang Q; Li Z; Li Y; Liu X; Dong B; Li N; Gao J; Shen L
    BMC Cancer; 2015 Nov; 15():894. PubMed ID: 26560145
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of trastuzumab and afatinib on kinase activity in gastric cancer cell lines.
    Keller S; Zwingenberger G; Ebert K; Hasenauer J; Wasmuth J; Maier D; Haffner I; Schierle K; Weirich G; Luber B
    Mol Oncol; 2018 Apr; 12(4):441-462. PubMed ID: 29325228
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hyperactivation of HER2-SHCBP1-PLK1 axis promotes tumor cell mitosis and impairs trastuzumab sensitivity to gastric cancer.
    Shi W; Zhang G; Ma Z; Li L; Liu M; Qin L; Yu Z; Zhao L; Liu Y; Zhang X; Qin J; Ye H; Jiang X; Zhou H; Sun H; Jiao Z
    Nat Commun; 2021 May; 12(1):2812. PubMed ID: 33990570
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Involvement of miR-770-5p in trastuzumab response in HER2 positive breast cancer cells.
    Noyan S; Gurdal H; Gur Dedeoglu B
    PLoS One; 2019; 14(4):e0215894. PubMed ID: 31009516
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increasing HER2 α2,6 sialylation facilitates gastric cancer progression and resistance via the Akt and ERK pathways.
    Liu N; Zhu M; Linhai Y; Song Y; Gui X; Tan G; Li J; Liu Y; Deng Z; Chen X; Wang J; Jia L; He X; Wang X; Lin S
    Oncol Rep; 2018 Nov; 40(5):2997-3005. PubMed ID: 30226606
    [TBL] [Abstract][Full Text] [Related]  

  • 9. POU4F1 confers trastuzumab resistance in HER2-positive breast cancer through regulating ERK1/2 signaling pathway.
    Wu D; Jia HY; Wei N; Li SJ
    Biochem Biophys Res Commun; 2020 Dec; 533(3):533-539. PubMed ID: 32988584
    [TBL] [Abstract][Full Text] [Related]  

  • 10. miR-301a-3p induced by endoplasmic reticulum stress mediates the occurrence and transmission of trastuzumab resistance in HER2-positive gastric cancer.
    Guo J; Zhong X; Tan Q; Yang S; Liao J; Zhuge J; Hong Z; Deng Q; Zuo Q
    Cell Death Dis; 2021 Jul; 12(7):696. PubMed ID: 34257270
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The anti-HER3 antibody in combination with trastuzumab exerts synergistic antitumor activity in HER2-positive gastric cancer.
    Wang Q; Zhang X; Shen E; Gao J; Cao F; Wang X; Li Y; Tian T; Wang J; Chen Z; Wang J; Shen L
    Cancer Lett; 2016 Sep; 380(1):20-30. PubMed ID: 27317872
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ultrasound Microbubbles Mediated Sonosensitizer and Antibody Co-delivery for Highly Efficient Synergistic Therapy on HER2-Positive Gastric Cancer.
    Sun L; Zhang J; Xu M; Zhang L; Tang Q; Chen J; Gong M; Sun S; Ge H; Wang S; Liang X; Cui L
    ACS Appl Mater Interfaces; 2022 Jan; 14(1):452-463. PubMed ID: 34961307
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An FGFR3 Autocrine Loop Sustains Acquired Resistance to Trastuzumab in Gastric Cancer Patients.
    Piro G; Carbone C; Cataldo I; Di Nicolantonio F; Giacopuzzi S; Aprile G; Simionato F; Boschi F; Zanotto M; Mina MM; Santoro R; Merz V; Sbarbati A; de Manzoni G; Scarpa A; Tortora G; Melisi D
    Clin Cancer Res; 2016 Dec; 22(24):6164-6175. PubMed ID: 27267856
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination of novel HER2-targeting antibody 1E11 with trastuzumab shows synergistic antitumor activity in HER2-positive gastric cancer.
    Ko BK; Lee SY; Lee YH; Hwang IS; Persson H; Rockberg J; Borrebaeck C; Park D; Kim KT; Uhlen M; Lee JS
    Mol Oncol; 2015 Feb; 9(2):398-408. PubMed ID: 25306393
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HOTAIR Competitively Binds MiRNA330 as a Molecular Sponge to Increase the Resistance of Gastric Cancer to Trastuzumab.
    Bie L; Luo S; Li D; Wei Y; Mu Y; Chen X; Wang S; Guo P; Lu X
    Curr Cancer Drug Targets; 2020; 20(9):700-709. PubMed ID: 32364078
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced antitumor activity of trastuzumab emtansine (T-DM1) in combination with pertuzumab in a HER2-positive gastric cancer model.
    Yamashita-Kashima Y; Shu S; Harada N; Fujimoto-Ouchi K
    Oncol Rep; 2013 Sep; 30(3):1087-93. PubMed ID: 23783223
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Macrophages stimulate gastric and colorectal cancer invasion through EGFR Y(1086), c-Src, Erk1/2 and Akt phosphorylation and smallGTPase activity.
    Cardoso AP; Pinto ML; Pinto AT; Oliveira MI; Pinto MT; Gonçalves R; Relvas JB; Figueiredo C; Seruca R; Mantovani A; Mareel M; Barbosa MA; Oliveira MJ
    Oncogene; 2014 Apr; 33(16):2123-33. PubMed ID: 23644655
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Establishment of a Patient-derived Xenograft for Development of Personalized HER2-targeting Therapy in Gastric Cancer.
    Shin SH; Park SS; Ju EJ; Park J; Ko EJ; Hwang JJ; Suh YA; Jang SJ; Lee JS; Ko BK; Kim KT; Lee JS; Song SY; Jeong SY; Choi EK
    Anticancer Res; 2018 Jan; 38(1):287-293. PubMed ID: 29277785
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The microRNA-21/PTEN pathway regulates the sensitivity of HER2-positive gastric cancer cells to trastuzumab.
    Eto K; Iwatsuki M; Watanabe M; Ida S; Ishimoto T; Iwagami S; Baba Y; Sakamoto Y; Miyamoto Y; Yoshida N; Baba H
    Ann Surg Oncol; 2014 Jan; 21(1):343-50. PubMed ID: 24154840
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oncolytic reovirus combined with trastuzumab enhances antitumor efficacy through TRAIL signaling in human HER2-positive gastric cancer cells.
    Hamano S; Mori Y; Aoyama M; Kataoka H; Tanaka M; Ebi M; Kubota E; Mizoshita T; Tanida S; Johnston RN; Asai K; Joh T
    Cancer Lett; 2015 Jan; 356(2 Pt B):846-54. PubMed ID: 25444894
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.